Dr Pepper

There are still around 35 drinking occasions over the course of a week, but beverage categories are changing. Pic: Getty/Kwangmoozaa

The last 30 years in beverages: How have consumers changed?

By Beth Newhart

While soda may have dominated shelves in the 1990s, today’s shoppers are seeking increasingly sophisticated functional beverages. Data company Kantar has analyzed consumer behavior in a new report that highlights the last three decades in the US beverage...

Carbonated soft drinks, water, coffee, energy drinks and sports drinks are the top beverages in c-stores. Pic: Getty/Sarah Casillas

Convenience store beverage purchases rise in the US

By Beth Newhart

Convenience store and gas station shopping habits for US consumers are analysed in GasBuddy’s 2019 C-Store Beverage Study, showing more impulse buys and higher demand for bottled water.

The machines are currently available to preorder online and retail for $399.

Drinkworks Home Bar expands beyond St. Louis

By Beth Newhart

A collaboration between AB InBev and Keurig Dr Pepper is bringing its Drinkworks pilot program to new markets this spring. The Drinkworks Home Bar by Keurig is now available statewide in Missouri and Florida.

Re-positioning soda and co-locating CPG divisions are just some of big brands' strategies. Pic: Getty/jonnysek

BEVERAGE FORUM 2019

How big soda is taking an ‘honest’ approach to consumer health habits

By Beth Newhart

PepsiCo, Keurig Dr Pepper (KDP) and other major soda brands are still learning to grapple with the health and wellness wave that’s causing consumers to drop their sugary drinks for something ‘better-for-you’. Executives spoke at the 2019 Beverage Forum...

ABA represents Coca-Cola, PepsiCo and Keurig Dr. Pepper. Pic: ©GettyImages/celsopupo

American Beverage Association appoints new CEO

By Beth Newhart

The American Beverage Association (ABA) has appointed Katherine Lugar as CEO and president, effective later this year. She will replace Susan K. Neely, who served in the role for 13 years.

It's been an action-packed year for the beverage world. Here are some of the highlights. (Pic:iStock/marekuliasz)

The year that was: Headlines of 2016

By Rachel Arthur

From mergers and acquisitions to innovations in packaging and flavors, we take a look back over some of the headlines of 2016. 

Dr Pepper invests $15m in minority stake in Bai Brands

Dr Pepper invests $15m in minority stake in Bai Brands

By Elaine Watson

Dr Pepper Snapple Group has invested $15m in a minority stake in Bai Brands, which has generated explosive growth in multiple retail channels with its 'antioxidant infusion' low-calorie Bai5 beverages.

Keurig Green Mountain ties up with Dr Pepper on Keurig Cold

Keurig Green Mountain teams up with Dr Pepper on Keurig Cold

By Elaine Watson

Keurig Green Mountain and Dr Pepper Snapple Group (DPS) have struck a deal to develop products for the hotly-anticipated Keurig Cold at-home beverage system, following Keurig’s 2014 deal to work with Coca-Cola on the Cold platform.

PepsiCo, Goya Foods, sued over 4-MEI

PepsiCo and Goya Foods targeted in lawsuit over 4-MEI

By Elaine WATSON

First the report, now the class action lawsuits: PepsiCo and Goya Foods - who were both cited in a recent report from product testing firm Consumer Reports about allegedly “concerning” 4-MEI levels in soft drinks - have been targeted in lawsuits filed...

US C-Stores: Ditching Dr Pepper TEN, sceptical on natural sweeteners?

'Energy is what the younger consumer identifies with': Retailer

US C-Stores: Ditching Dr Pepper TEN, sceptical on natural sweeteners?

By Ben BOUCKLEY

US C-Stores owners do not believe all-natural sweeteners can reverse flagging soda sales, says one US analyst, who is also advising Dr Pepper to stop investing in its low-calorie TEN platform.

Caramel colors: Prop 65 4-MeI levels in Coke, Pepsi

Caramel colors under fire again: Is there a safe level of 4-MeI?

By Elaine WATSON

The FDA says it has “no reason to believe” that 4-MeI - an impurity generated during the manufacture of caramel colors III and IV - poses a health risk at current dosage levels, but says it is reviewing new data to determine whether it needs to revise...